Biotech News

Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer

Sensei Biotherapeutics (SNSE)Sensei Biotherapeutics2026-06-25 13:46 ESTFinancing

— Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement — — Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock expected to begin trading under the ticker symbol

Open original release

Related news

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer

View all latest news

Sensei Biotherapeutics

Sensei Biotherapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

SNSESensei Biotherapeutics2026-06-26 07:29 EST

Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer

SNSESensei Biotherapeutics2026-06-26 07:29 EST

Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

SNSESensei Biotherapeutics2026-06-26 07:29 EST

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

SNSESensei Biotherapeutics2026-06-26 07:29 EST

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

SNSESensei Biotherapeutics2026-06-26 07:29 EST

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

Stock data

Close: —
Market cap: —
Exchange: NYSE
Sector: Biotechnology
Location: United States